GSK's experimental drug Ris-Rez has delivered promising results in a late-stage trial for advanced or relapsed small-cell lung cancer. The antibody-drug conjugate, licensed from China's Hansoh Pharma, demonstrated statistically significant and clinically meaningful improvements in overall survival compared to standard care. The drug targets the B7H3 protein found on cancer cells and is also being explored for other tumor types, including prostate cancer.
GSK's experimental cancer drug Ris-Rez has cleared a major hurdle, showing "statistically significant and clinically meaningful" improvements in overall survival versus standard care in a late-stage trial for patients with advanced or relapsed small-cell lung cancer (SCLC). SCLC is one of the most aggressive and difficult-to-treat cancers, making this a notable development for a disease with limited therapeutic options.
Ris-Rez is an antibody-drug conjugate (ADC) — a class of targeted therapies that deliver chemotherapy directly to cancer cells — and works by homing in on the B7H3 protein expressed on tumor cells. GSK licensed the drug from China's Hansoh Pharma for rights outside of China, and is developing it across multiple tumor types, including lung and prostate cancer.
Key Takeaways:
Why it matters: A positive late-stage survival signal in SCLC could position Ris-Rez as a meaningful new treatment option in a space that has seen little innovation, while also validating GSK's broader bet on ADC-based oncology therapies.
